Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.

Daniel EdmonstonHillary MulderElizabeth LydonKaren ChiswellZachary LampronChristina ShayKeith MarsoloRaj C ShahW Schuyler JonesHoward GordonWenke HwangIsabella AyoubDaniel FordAlanna ChamberlainAjaykumar RaoVivian FonsecaAlexander ChangFaraz AhmadAdriana HungKelly HuntJaved ButlerHayden B BosworthNeha Pagidipati

Published in: Journal of the American College of Cardiology (2024)

SGLT2i and GLP-1 RAs led to similar kidney and cardiovascular outcomes in people with T2D, though SGLT2i initiation was associated with a lower risk of 40% eGFR decline. (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease; NCT05465317).

Keyphrases

type diabetes
chronic kidney disease
glycemic control
small cell lung cancer
randomized controlled trial
end stage renal disease
cardiovascular disease
insulin resistance
systematic review
epidermal growth factor receptor
tyrosine kinase
wild type
skeletal muscle